All Updates

All Updates

icon
Filter
Regulation/policy
Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision
Precision Medicine
Dec 17, 2023
This week:
Partnerships
Gpower partners with Amorepacific to develop dual-function beauty tech devices
Beauty Tech
Yesterday
Funding
Brightwave raises USD 15 million in Series A funding to improve knowledge graph and expand operations
Capital Markets Tech
Yesterday
Funding
Matia raises USD 10.5 million in seed funding from Leaders Fund
Data Infrastructure & Analytics
Yesterday
Partnerships
GitHub Copilot integrates models from Anthropic, Google, and OpenAI
Foundation Models
Yesterday
Partnerships
Axtra3D partners with Ridix for 3D printer distribution in Italy
Additive Manufacturing
Yesterday
Funding
Aignostics raises USD 34 million in Series B funding to create new biopharmaceutical products
Precision Medicine
Yesterday
Partnerships
Monte Rosa Therapeutics partners with Novartis to develop VAV1 molecular glue degrader medicines
Precision Medicine
Yesterday
Funding
Curis secures USD 12.1 million in direct offering and private placement to fund R&D and general corporate purposes
Precision Medicine
Yesterday
Funding
Pathos raises USD 62 million in Series C funding to expand research team and advance AI platform
Precision Medicine
Yesterday
Funding
Pathos raises USD 62 million in Series C funding to expand research team and advance AI platform
AI Drug Discovery
Yesterday
Precision Medicine

Precision Medicine

Dec 17, 2023

Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision

Regulation/policy

  • Illumina announced that the company will divest GRAIL via a third-party sale or capital markets transaction, as per the European Commission's divestiture order, to finalize the terms by the second quarter of 2024.

  • On December 15, the US Fifth Circuit Court of Appeals issued its decision relating to Illumina vs. the Federal Trade Commission. Considering this opinion, Illumina has opted not to pursue further appeals of this decision. 

  • GRAIL would continue to be held separately, along with committed funding from Illumina for the company's business through the divestment process. Prior to this, Illumina had spun off GRAIL in 2016 but retained a 12% stake and subsequently reacquired the company in 2021.

  • GRAIL has developed the Galleri test, the first clinically validated MCED test that reportedly can detect a signal shared by more than 50 types of cancer with 99.5% specificity and predict the cancer signal origin with high accuracy to help guide the next steps. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.